MediGene Acquires Patents on Anti-Cancer Drugs Under Development
License agreements with the University of Chicago guarantee exclusive worldwide rights to the most important groups of patents in the field of oncolytic Herpes Simplex Viruses (HSV)
09-Oct-2003 -
The German-American biotechnology company MediGene (Frankfurt, Prime Standard: MDG) has acquired additional patents and patent applications for the anti-cancer drug candidates NV1020 and G207 as well as for the underlying HSV technology. License agreements concluded with the University of Chicago ...
biotechnology
cancer therapy
chemotherapy
+8